文献速递肿瘤 PET/CT

基于NCCN-IPI与治疗后Deauville评分的结内外周T细胞淋巴瘤风险分层模型

A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-07-28

该研究回顾性分析326例新诊断结内外周T细胞淋巴瘤(PTCL)患者基线与治疗后PET/CT数据,建立整合治疗后Deauville评分与治疗前NCCN-IPI的三组风险模型,并用79例独立前瞻性队列验证。模型与无进展生存和总生存显著相关,验证队列结果相似。

要点

  • 治疗后Deauville评分1/2、3、4/5与NCCN-IPI低、低中、高中、高危均独立关联无进展生存。
  • 三组风险模型:低危、高危、治疗失败组5年无进展生存分别为70.3%、31.4%、4.7%。
  • 三组5年总生存分别为82.1%、45.5%、14.7%,独立验证队列结果相似。

核心结论

  • 整合治疗后Deauville评分与治疗前NCCN-IPI的风险分层模型是预测结内PTCL患者治疗失败的有力工具。

研究设计与样本

  • 回顾性分析2005年1月至2016年6月间326例新诊断结内PTCL患者,均具备基线与治疗后PET/CT数据。
  • 最终模型在79例独立前瞻性队列中进行验证。

主要发现

  • 治疗后Deauville评分(1/2、3、4/5)与无进展生存独立相关,HR分别为1.00 vs 2.16(95%CI 1.47-3.18)vs 7.86(95%CI 5.66-10.92),P<0.001。
  • NCCN-IPI(低、低中、高中、高危)与无进展生存独立相关,HR分别为1.00 vs 2.31(95%CI 1.20-4.41)vs 4.42(95%CI 2.36-8.26)vs 7.09(95%CI 3.57-14.06),P<0.001。
  • 三组风险模型与无进展生存显著相关,5年无进展生存率分别为低危组70.3%、高危组31.4%、治疗失败组4.7%,P<0.001。
  • 三组风险模型与总生存显著相关,5年总生存率分别为低危组82.1%、高危组45.5%、治疗失败组14.7%,P<0.001。
  • 独立验证队列中观察到相似的关联。

关键数值与推荐

  • 低危组:NCCN-IPI低或低中且治疗后Deauville评分1或2,或NCCN-IPI低且Deauville评分3。
  • 高危组:NCCN-IPI高或高中且Deauville评分1/2或3,或NCCN-IPI低中且Deauville评分3。
  • 治疗失败组:Deauville评分4或5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. METHODS: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. RESULTS: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95% CI 1.47-3.18) vs. 7.86 (5.66-10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95% CI 1.20-4.41) vs. 4.42 (2.36-8.26) vs. 7.09 (3.57-14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3%, 31.4%, and 4.7%; P < 0.001) and overall survival (5-year, 82.1%, 45.5%, and 14.7%; P < 0.001). Similar associations were also observed in the independent validation cohort. CONCLUSION: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yhim HY, Park Y, Han YH, et al. A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. Eur J Nucl Med Mol Imaging. 2018. PMID: 30056546. doi:10.1007/s00259-018-4093-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。